Avalo Therapeutics, Inc. (AVTX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Avalo Therapeutics, Inc. (AVTX) is down 23.1% since the beginning of the year. At $14 per share, AVTX is trading 42.5% below its 52-week high of $24. Investors who bought $1,000 worth of AVTX shares 5 years ago would now be looking at an investment worth $2.

Avalo Therapeutics, Inc. (AVTX) has returned -23.13% so far this year and 217.27% over the past 12 months. Over the last ten years, AVTX has returned -45.81% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.

Based on dividend-adjusted daily data since Nov 13, 2015, AVTX's average daily return is +0.12%, while the average monthly return is +1.38%. At this rate, an investment would double in approximately 4.2 years.

Historically, 45% of months were positive and 55% were negative. The best month was Mar 2024 with a return of +393.2%, while the worst month was Jun 2023 at -87.6%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 7 months.

On a daily basis, AVTX closed higher 44% of trading days. The best single day was Mar 28, 2024 with a return of +357.9%, while the worst single day was Jun 26, 2023 at -88.7%.

Avalo Therapeutics, Inc. has an annualized alpha of 17.97%, beta of 1.04, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since November 16, 2015.

• This stock participated in 206.89% of S&P 500 Index downside but only -43.20% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

AVTX ranks 90 for risk / return — in the top 90% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Avalo Therapeutics, Inc. (AVTX) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Avalo Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Avalo Therapeutics, Inc. was 99.98%, occurring on May 28, 2025. The portfolio has not yet recovered.

The current Avalo Therapeutics, Inc. drawdown is 99.93%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Avalo Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Avalo Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.